Humacyte, Inc. Common Stock (HUMA)

Price$0.69

Favorite Metrics

Price vs S&P 500 (26W)-63.22%

Price vs S&P 500 (4W)-18.79%

Market Capitalization$157.68M

All Metrics

Book Value / Share (Quarterly)$0.02

P/TBV (Annual)2.23x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.38%

Cash Flow / Share (Quarterly)$-0.55

Price vs S&P 500 (YTD)-30.24%

Net Profit Margin (TTM)-182.79%

EPS (TTM)$-0.19

10-Day Avg Trading Volume4.76M

EPS Excl Extra (TTM)$-0.19

Revenue Growth (5Y)-19.92%

EPS (Annual)$-0.26

ROI (Annual)-60.09%

Gross Margin (Annual)-376.05%

Net Profit Margin (5Y Avg)-2142.40%

Cash / Share (Quarterly)$0.26

ROA (Last FY)-35.09%

EBITD / Share (TTM)$-0.40

ROE (5Y Avg)-451.43%

Operating Margin (TTM)-5796.03%

Cash Flow / Share (Annual)$-0.55

P/B Ratio50.72x

P/B Ratio (Quarterly)59.62x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)99.04x

Net Interest Coverage (TTM)-78.58x

ROA (TTM)-32.07%

EV / EBITDA (TTM)3.64x

EPS Incl Extra (Annual)$-0.26

Current Ratio (Annual)3.69x

Quick Ratio (Quarterly)2.78x

3-Month Avg Trading Volume6.33M

52-Week Price Return-54.18%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.36

P/S Ratio (Annual)77.37x

Asset Turnover (Annual)0.02x

52-Week High$2.93

Operating Margin (5Y Avg)-4737.98%

EPS Excl Extra (Annual)$-0.26

CapEx CAGR (5Y)22.54%

26-Week Price Return-54.47%

Quick Ratio (Annual)2.78x

13-Week Price Return-37.70%

Total Debt / Equity (Annual)20.86x

Current Ratio (Quarterly)3.69x

Enterprise Value$172.027

Revenue / Share Growth (5Y)-26.49%

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2003.58%

Cash / Share (Annual)$0.26

3-Month Return Std Dev121.15%

Net Income / Employee (TTM)$-0

ROE (Last FY)-1313.38%

Net Interest Coverage (Annual)-25.13x

EPS Basic Excl Extra (Annual)$-0.26

Receivables Turnover (TTM)0.05x

Total Debt / Equity (Quarterly)20.86x

EPS Incl Extra (TTM)$-0.19

Receivables Turnover (Annual)15.70x

ROI (TTM)-25.54%

P/S Ratio (TTM)90.78x

Pretax Margin (5Y Avg)-2142.40%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$1.13

Price vs S&P 500 (52W)-89.28%

Year-to-Date Return-26.10%

5-Day Price Return5.98%

EPS Normalized (Annual)$-0.26

ROA (5Y Avg)-48.93%

Net Profit Margin (Annual)-2003.58%

Month-to-Date Return17.00%

Cash Flow / Share (TTM)$-0.79

EBITD / Share (Annual)$-0.40

Operating Margin (Annual)-6398.63%

LT Debt / Equity (Annual)11.40x

ROI (5Y Avg)-61.19%

LT Debt / Equity (Quarterly)11.40x

EPS Basic Excl Extra (TTM)$-0.19

P/TBV (Quarterly)7.06x

P/B Ratio (Annual)59.62x

Pretax Margin (TTM)-182.79%

Book Value / Share (Annual)$0.02

Price vs S&P 500 (13W)-40.57%

Beta2.25x

Revenue / Share (TTM)$0.01

ROE (TTM)-161.95%

52-Week Low$0.55

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.08

Industry Peers — Biological Products(89)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HUMAHumacyte, Inc. Common Stock	90.78x	—	—	—	$0.69
AMGNAmgen Inc	5.20x	9.95%	73.30%	2.93%	$350.16
GILDGilead Sciences Inc	5.71x	2.40%	78.83%	133.64%	$135.87
ARGXargenx SE American Depositary Shares	12.59x	89.56%	150.91%	—	$834.45
BNTXBioNTech SE American Depositary Share	9.06x	-11.81%	84.21%	—	$105.19
BIIBBiogen Inc. Common Stock	2.72x	2.22%	75.69%	-18.77%	$183.34
MRNAModerna, Inc. Common Stock	10.91x	-39.93%	70.32%	—	$54.59
NBIXNeurocrine Biosciences Inc	4.64x	21.45%	98.18%	2.31%	$131.59
EXELExelixis Inc	4.89x	6.85%	96.39%	31.10%	$43.61
TECHBio-Techne Corp.	7.72x	1.64%	66.60%	-20.58%	$60.58
IBRXImmunityBio, Inc. Common Stock	74.42x	668.31%	99.34%	—	$8.20

About

Humacyte develops acellular bioengineered human tissues for therapeutic applications in vascular disease, peripheral arterial disease, dialysis access, and organ reconstruction. The company's tissue engineering platform aims to create universally implantable solutions that reduce rejection risk and address significant unmet medical needs across multiple therapeutic areas.